Tag: cause

NORTHBROOK, Ill., July 30, 2025 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: ...

Two Core Drill Rigs Arriving in August WINNEMUCCA, Nev., July 30, 2025 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or the "Company") today...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, July 30, 2025 /CNW/ - Palisades Goldcorp Ltd. (TSXV:...

BROSSARD, QC, July 30, 2025 /CNW/ - G Mining Ventures Corp. ("GMIN" or the "Corporation" or "we") (TSX: GMIN) (OTCQX: GMINF) is pleased to announce...

BROSSARD, QC, July 30, 2025 /PRNewswire/ - G Mining Ventures Corp. ("GMIN" or the "Corporation" or "we") (TSX: GMIN) (OTCQX: GMINF) is pleased to announce...

TSX: TVE CALGARY, AB, July 30, 2025 /CNW/ - Tamarack Valley Energy Ltd. ("Tamarack" or the "Company") (TSX: TVE) is pleased to announce its financial...

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

MUMBAI, India, July 30, 2025 /PRNewswire/ -- On July 20, over 6,500 runners participated in the 14th Hexaware Dream Runners Half Marathon (DRHM) in Chennai,...

Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the customer’s proactive work ability management and employee well-being initiatives.

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about July 31, 2025, subject to the satisfaction of customary closing conditions.